<p><strong>Pediatric Use</strong>: Safety and effectiveness of Cabergoline in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.<br />
<br />
<strong>Use in patients with hepatic impairment</strong>: Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering Cabergoline to patients with hepatic impairment.</p>